相对于基于人群的对照，上尿路尿路上皮癌诊断对预期寿命的影响：一项回顾性分析。

IF 1.3 4区医学 Q3 UROLOGY & NEPHROLOGY

Urologia Internationalis Pub Date : 2025-09-02 DOI:10.1159/000548236

Carolin Siech, Mario de Angelis, Letizia Maria Ippolita Jannello, Francesco Di Bello, Natali Rodriguez Peñaranda, Jordan A Goyal, Fred Saad, Shahrokh F Shariat, Salvatore Micali, Nicola Longo, Ottavio de Cobelli, Alberto Briganti, Mike Wenzel, Philipp Mandel, Luis A Kluth, Felix K H Chun, Pierre I Karakiewicz

{"title":"相对于基于人群的对照，上尿路尿路上皮癌诊断对预期寿命的影响：一项回顾性分析。","authors":"Carolin Siech, Mario de Angelis, Letizia Maria Ippolita Jannello, Francesco Di Bello, Natali Rodriguez Peñaranda, Jordan A Goyal, Fred Saad, Shahrokh F Shariat, Salvatore Micali, Nicola Longo, Ottavio de Cobelli, Alberto Briganti, Mike Wenzel, Philipp Mandel, Luis A Kluth, Felix K H Chun, Pierre I Karakiewicz","doi":"10.1159/000548236","DOIUrl":null,"url":null,"abstract":"Introduction: The aim of the study was to examine 5-year overall survival (OS) of upper urinary tract urothelial carcinoma (UTUC) patients versus age- and sex-matched population-based controls.Methods: Within Surveillance, Epidemiology, and End Results database (2004-2020), we identified newly diagnosed (2004-2015) UTUC patients. Relying on Social Security Administration Life Tables (2004-2020), age- and sex- matched population-based controls were simulated (Monte Carlo simulation).Results: Of 10,140 UTUC patients, 3,984 (39%) exhibited localized, 4,904 (49%) locally advanced, and 1,252 (12%) metastatic stages. At 5 years of follow-up, the OS rate was 41 versus 78% (Δ 37%) in UTUC patients versus controls. According to stage, OS difference was greatest in metastatic stage (4 vs. 75%; Δ 71%), followed by locally advanced (36 vs. 78%; Δ 42%) and localized stages (58 vs. 78%; Δ 20%). At 5 years of follow-up, the CSM rate was 44%, and the OCM rate was 16%. According to stage, CSM and OCM rates were 88 and 7% in metastatic, 49 and 15% in locally advanced, and 22 and 19% in localized stage UTUC patients.Conclusion: UTUC patients may experience worse OS compared to population-based controls. The most pronounced differences in the 5-year OS were recorded in metastatic and locally advanced stages, suggesting a potentially substantial impact of UTUC on patients' life expectancy.","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-10"},"PeriodicalIF":1.3000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503815/pdf/","citationCount":"0","resultStr":"{\"title\":\"Upper Urinary Tract Urothelial Carcinoma Diagnosis Effect on Life Expectancy Relative to Population-Based Controls: A Retrospective Analysis.\",\"authors\":\"Carolin Siech, Mario de Angelis, Letizia Maria Ippolita Jannello, Francesco Di Bello, Natali Rodriguez Peñaranda, Jordan A Goyal, Fred Saad, Shahrokh F Shariat, Salvatore Micali, Nicola Longo, Ottavio de Cobelli, Alberto Briganti, Mike Wenzel, Philipp Mandel, Luis A Kluth, Felix K H Chun, Pierre I Karakiewicz\",\"doi\":\"10.1159/000548236\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: The aim of the study was to examine 5-year overall survival (OS) of upper urinary tract urothelial carcinoma (UTUC) patients versus age- and sex-matched population-based controls.Methods: Within Surveillance, Epidemiology, and End Results database (2004-2020), we identified newly diagnosed (2004-2015) UTUC patients. Relying on Social Security Administration Life Tables (2004-2020), age- and sex- matched population-based controls were simulated (Monte Carlo simulation).Results: Of 10,140 UTUC patients, 3,984 (39%) exhibited localized, 4,904 (49%) locally advanced, and 1,252 (12%) metastatic stages. At 5 years of follow-up, the OS rate was 41 versus 78% (Δ 37%) in UTUC patients versus controls. According to stage, OS difference was greatest in metastatic stage (4 vs. 75%; Δ 71%), followed by locally advanced (36 vs. 78%; Δ 42%) and localized stages (58 vs. 78%; Δ 20%). At 5 years of follow-up, the CSM rate was 44%, and the OCM rate was 16%. According to stage, CSM and OCM rates were 88 and 7% in metastatic, 49 and 15% in locally advanced, and 22 and 19% in localized stage UTUC patients.Conclusion: UTUC patients may experience worse OS compared to population-based controls. The most pronounced differences in the 5-year OS were recorded in metastatic and locally advanced stages, suggesting a potentially substantial impact of UTUC on patients' life expectancy.\",\"PeriodicalId\":23414,\"journal\":{\"name\":\"Urologia Internationalis\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503815/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologia Internationalis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000548236\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Internationalis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000548236","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：比较上尿路尿路上皮癌（UTUC）患者与年龄和性别匹配人群的5年总生存率（OS）。方法：在监测、流行病学和最终结果数据库（2004-2020）中，我们确定了新诊断的（2004-2015）UTUC患者。根据社会保障局生命表（2004-2020），模拟了年龄和性别匹配的基于人口的控制（蒙特卡洛模拟）。结果：在10140例UTUC患者中，3984例（39%）表现为局部转移期，4904例（49%）表现为局部晚期，1252例（12%）表现为转移期。在5年的随访中，UTUC患者的OS率为41%，而对照组为78% （Δ 37%）。根据分期，转移期OS差异最大（4 vs 75%； Δ 71%），其次是局部晚期（36 vs 78%； Δ 42%）和局部期（58 vs 78%； Δ 20%）。随访5年，CSM率为44%，OCM率为16%。根据分期，转移性CSM和OCM的发生率分别为88%和7%，局部晚期为49%和15%，局部期UTUC为22%和19%。结论：与基于人群的对照组相比，UTUC患者可能经历更差的OS。5年OS中最显著的差异发生在转移性和局部晚期，这表明UTUC对患者预期寿命有潜在的重大影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Upper Urinary Tract Urothelial Carcinoma Diagnosis Effect on Life Expectancy Relative to Population-Based Controls: A Retrospective Analysis.

Introduction: The aim of the study was to examine 5-year overall survival (OS) of upper urinary tract urothelial carcinoma (UTUC) patients versus age- and sex-matched population-based controls.

Methods: Within Surveillance, Epidemiology, and End Results database (2004-2020), we identified newly diagnosed (2004-2015) UTUC patients. Relying on Social Security Administration Life Tables (2004-2020), age- and sex- matched population-based controls were simulated (Monte Carlo simulation).

Results: Of 10,140 UTUC patients, 3,984 (39%) exhibited localized, 4,904 (49%) locally advanced, and 1,252 (12%) metastatic stages. At 5 years of follow-up, the OS rate was 41 versus 78% (Δ 37%) in UTUC patients versus controls. According to stage, OS difference was greatest in metastatic stage (4 vs. 75%; Δ 71%), followed by locally advanced (36 vs. 78%; Δ 42%) and localized stages (58 vs. 78%; Δ 20%). At 5 years of follow-up, the CSM rate was 44%, and the OCM rate was 16%. According to stage, CSM and OCM rates were 88 and 7% in metastatic, 49 and 15% in locally advanced, and 22 and 19% in localized stage UTUC patients.

Conclusion: UTUC patients may experience worse OS compared to population-based controls. The most pronounced differences in the 5-year OS were recorded in metastatic and locally advanced stages, suggesting a potentially substantial impact of UTUC on patients' life expectancy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Urologia Internationalis 医学-泌尿学与肾脏学

CiteScore

3.30

自引率

6.20%

发文量

审稿时长

3-8 weeks

期刊介绍： Concise but fully substantiated international reports of clinically oriented research into science and current management of urogenital disorders form the nucleus of original as well as basic research papers. These are supplemented by up-to-date reviews by international experts on the state-of-the-art of key topics of clinical urological practice. Essential topics receiving regular coverage include the introduction of new techniques and instrumentation as well as the evaluation of new functional tests and diagnostic methods. Special attention is given to advances in surgical techniques and clinical oncology. The regular publication of selected case reports represents the great variation in urological disease and illustrates treatment solutions in singular cases.